查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1397435

全球非處方藥和補充劑市場：2024-2034

OTC Drugs & Dietary Supplements Market Report 2024-2034
出版日期: | 出版商: Visiongain | 英文 337 Pages | 商品交期: 最快1-2個工作天內

價格

到 2034 年，全球非處方藥和補充劑市場規模預計將以 6.7% 的複合年增長率成長。

以處方藥為中心的傳統藥物模式正經歷變革期。 製藥公司正在策略性地重新調整重點，以滿足對非處方藥和補充劑不斷增長的需求。 這種轉變背後有許多因素，包括消費者偏好的變化、自我保健意識的進步以及擴大市場研究的潛力。 這項轉變的主要影響之一是增加了消費者獲得藥品的機會。 非處方藥和補充劑提供了一種無需處方即可治療常見疾病的便捷方法，使個人能夠掌控自己的健康。 這一轉變符合更廣泛的自我管理醫療保健和預防性健康的全球趨勢。 隨著產業不斷發展，密切監控這些變化如何影響消費者行為、市場動態和監管環境至關重要。 正在進行的轉型代表了醫療保健領域的一個重要裡程碑，並強調了個人健康管理中授權的重要性。

監管機構在確保非處方藥和補充劑符合最高品質和有效性標準方面發揮著至關重要的作用。 雖然監管變化帶來了積極成果，但也給行業參與者帶來了挑戰。 滿足新的合規性要求需要消耗大量資源，公司必須應對不斷變化的環境，以確保其產品符合最新標準。 持續監控和調整監管變化的需求是在場外交易市場保持成功的關鍵面向。 監管機構變化的影響超越國界，影響全球場外交易市場的動態。 在多個地區營運的公司必須應對不同的監管環境，並調整策略以滿足不同的要求。 對於那些努力在遵守當地法規的同時建立全球影響力的公司來說，這既是挑戰也是機會。

本報告調查了全球非處方藥和補充劑市場，提供了市場概況，分析了影響市場成長和市場機會的因素、市場規模的趨勢和預測，對各個細分市場和地區進行了詳細分析，總結了競爭格局、概況各大公司等

目錄

第 1 章報告概述

第 2 章執行摘要

第三章市場概述

  • 主要調查結果
  • 市場動態
    • 市場驅動因素
    • 市場限制因素
    • 市場機會
  • 新冠肺炎 (COVID-19) 影響分析
  • 波特五力分析
  • PEST分析

第四章非處方藥和補充劑市場分析：按類別

  • 主要調查結果
  • 市場吸引力指數
  • 市場規模趨勢與預測
  • 止痛藥
  • 感冒、咳嗽和流感產品
  • 胃腸道醫學
  • 眼科
  • 女性護理
  • 維生素補充劑
  • 助眠劑
  • 去疣劑
  • 小鼠護理產品
  • 植物
  • 禁煙產品
    • 市場規模趨勢與預測：按地區劃分
    • 市佔率：依地區劃分

第五章非處方藥和補充劑市場分析：按表格

  • 主要調查結果
  • 市場吸引力指數
  • 市場規模趨勢與預測
  • 平板電腦
  • 膠囊
  • 粉末
  • 軟膏
  • 軟膠囊
  • 液體
  • 其他
    • 市場規模趨勢與預測：按地區劃分
    • 市佔率：依地區劃分

第 6 章非處方藥和補充劑市場分析：按分銷管道

  • 主要調查結果
  • 市場吸引力指數
  • 市場規模趨勢與預測
  • 藥房
  • 維生素及保健食品店
  • 網路藥局
  • 雜貨店
    • 市場規模趨勢與預測：按地區劃分
    • 市佔率：依地區劃分

第 7 章非處方藥和補充劑市場分析：依產品類型

  • 主要調查結果
  • 市場吸引力指數
  • 市場規模趨勢與預測
  • 品牌
  • 通用
    • 市場規模趨勢與預測：按地區劃分
    • 市佔率：依地區劃分

第 8 章非處方藥和補充劑市場分析：按地區

  • 主要調查結果
  • 市場規模趨勢與預測

第九章北美OTC藥品及補充品市場分析

第10章歐洲非處方藥和補充劑市場分析

第 11 章亞太地區非處方藥和補充劑市場分析

第十二章拉丁美洲非處方藥和補充劑市場分析

第十三章中東和非洲非處方藥和補充劑市場分析

第十四章公司簡介

  • 競爭狀況
  • 戰略展望
  • Abbott
  • Amway Corporation
  • Bayer AG
  • Cipla, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd
  • GlaxoSmithKline plc
  • Herbalife Nutrition
  • Kenvue Inc.
  • Nestle SA
  • Perrigo Company Inc,
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd

第 15 章一般性評論/建議

  • Visiongain 概述
  • 給市場參與者的建議
Product Code: PHA1299

The global OTC Drugs & Dietary Supplements market is projected to grow at a CAGR of 6.7% by 2034.

“The OTC Drugs & Dietary Supplements Report 2024-2034”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Pharmaceutical companies transitioning from prescription medications to over-the-counter drugs

The traditional model of pharmaceuticals, dominated by prescription medications, is undergoing a transformative phase. Pharmaceutical companies are strategically realigning their focus to cater to the growing demand for OTC drugs and supplements. This transition is driven by various factors, including changing consumer preferences, advancements in self-care awareness, and the potential for expanded market reach. One of the primary impacts of this transition is the increased accessibility of medications for consumers. OTC drugs and supplements empower individuals to take charge of their health, providing a convenient avenue for managing common ailments without the need for a prescription. This shift aligns with a broader global trend towards self-directed healthcare and preventive wellness. As the industry continues to evolve, it is essential to monitor how these changes shape consumer behavior, market dynamics, and regulatory environments. The ongoing transformation signifies a significant milestone in healthcare, emphasizing the importance of empowering individuals in managing their well-being.

Evolving Regulatory Standardizations Will Limit the Growth

One of the key impacts of evolving regulatory bodies is the pursuit of harmonization and standardization. Regulatory agencies globally are working towards aligning standards to ensure consistency in the evaluation and approval processes for OTC drugs and supplements. This move aims to streamline market access, reduce trade barriers, and enhance the overall quality and safety of products available to consumers. Changing regulatory frameworks prioritize consumer safety and confidence by implementing stringent guidelines and monitoring mechanisms. The emphasis on transparency, clear labeling, and comprehensive product information is bolstering consumer trust in OTC products. Regulatory bodies play a pivotal role in ensuring that OTC drugs and supplements meet the highest standards of quality and efficacy. While regulatory changes bring positive outcomes, they also pose challenges for industry players. Adapting to new compliance requirements can be resource-intensive, and companies must navigate the evolving landscape to ensure that their products meet the latest standards. The need for continuous monitoring and adjustment to regulatory changes is a critical aspect of sustaining success in the OTC market. The impact of changing regulatory bodies extends beyond national borders, influencing the global OTC market dynamics. Companies operating in multiple regions must navigate diverse regulatory landscapes, adapting their strategies to comply with varying requirements. This presents both challenges and opportunities as companies strive to create a global presence while adhering to local regulations.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the OTC Drugs & Dietary Supplements Market evolving?
  • What is driving and restraining the OTC Drugs & Dietary Supplements Market?
  • How will each OTC Drugs & Dietary Supplements submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
  • How will the market shares for each OTC Drugs & Dietary Supplements submarket develop from 2024 to 2034?
  • What will be the main driver for the overall market from 2024 to 2034?
  • Will leading OTC Drugs & Dietary Supplements Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2034?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the OTC Drugs & Dietary Supplements projects for these leading companies?
  • How will the industry evolve during the period between 2024 and 2034? What are the implications of OTC Drugs & Dietary Supplements projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the OTC Drugs & Dietary Supplements Market?
  • Where is the OTC Drugs & Dietary Supplements Market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the OTC Drugs & Dietary Supplements Market today, and over the next 10 years:

  • Our 337-page report provides 123 tables and 192 charts/graphs exclusively to you
  • The report highlights key lucrative areas in the industry so you can target them - NOW
  • It contains in-depth analysis of global, regional and national sales and growth
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the OTC Drugs & Dietary Supplements Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares
  • You will find original analyses, with business outlooks and developments
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising OTC Drugs & Dietary Supplements prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

By Categories

  • Analgesics
  • Cold, cough and Flu Products
  • Gastrointestinal Products
  • Ophthalmic
  • Feminine Care
  • Vitamin and Dietary Supplements
  • Sleep Aids
  • Wart Removers
  • Mouth Care Products
  • Botanicals
  • Smoking Cessation Products

By Dosage Forms

  • Tablets
  • Capsules
  • Powder
  • Ointments
  • Soft Capsules
  • Liquids
  • Others

By Distribution Channel

  • Pharmacies
  • Vitamin & Health Food Store
  • Online Pharmacy
  • Grocery Stores

By Product Type

  • Branded
  • Generic

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America

  • U.S
  • Canada

Europe

  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

Leading companies profiled in the report:

  • Abbott
  • Amway Corporations
  • Bayer
  • Cipla Inc
  • Dr. Reddy's Laboratories
  • Glenmark Pharmaceuticals
  • GlaxoSmithKline plc
  • Herbalife Nutrition
  • Kenvue Inc. (Previously J&J Services Business Division)
  • Nestle
  • Perrigo Company Inc
  • Pfizer Inc
  • Sanofi
  • Sun Pharmaceuticals

Overall world revenue for OTC Drugs & Dietary Supplements Market, 2024 to 2034 in terms of value the market will surpass US$211.8 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the “OTC Drugs & Dietary Supplements Market, 2024 to 2034” report help you?

In summary, our 330+ page report provides you with the following knowledge:

  • Revenue forecasts to 2034 for OTC Drugs & Dietary Supplements Market, 2024 to 2034 Market, with forecasts for product and end-user, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2034 for five regional and 20 key national markets - See forecasts for the OTC Drugs & Dietary Supplements Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 14 of the major companies involved in the OTC Drugs & Dietary Supplements Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the OTC Drugs & Dietary Supplements Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to OTC Drugs & Dietary Supplements
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Pharmaceutical Companies switching from Rx to OTC Drugs
      • 3.2.1.2 Increasing Prevalence of Metabolic Disorders
      • 3.2.1.3 Growing Trend of Self-Medication
      • 3.2.1.4 Increasing Awareness of Nutraceutical Products
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Several concerns pertaining to incorrect diagnosis and substance abuse
      • 3.2.2.2 Challenging regulatory environment
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Increasing Demand for Preventive Healthcare solutions
      • 3.2.3.2 Growing Preference for Natural and Organic Products
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyers
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat from Substitutes
    • 3.4.5 Threat of New Entrants
  • 3.5 PEST Analysis

4 OTC Drugs & Dietary Supplements Analysis by Categories

  • 4.1 Key Findings
  • 4.2 Indication Segment: Market Attractiveness Index
  • 4.3 OTC Drugs & Dietary Supplements Size Estimation and Forecast by Categories
  • 4.4 Analgesics
    • 4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 Cold, Cough and Flu Products
    • 4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.5.2 Market Share by Region, 2024 & 2034 (%)
  • 4.6 Gastrointestinal Products
    • 4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.6.2 Market Share by Region, 2024 & 2034 (%)
  • 4.7 Ophthalmic
    • 4.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.7.2 Market Share by Region, 2024 & 2034 (%)
  • 4.8 Feminine Care
    • 4.8.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.8.2 Market Share by Region, 2024 & 2034 (%)
  • 4.9 Vitamin and Dietary Supplements
    • 4.9.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.9.2 Market Share by Region, 2024 & 2034 (%)
  • 4.10 Sleep Aids
    • 4.10.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.10.2 Market Share by Region, 2024 & 2034 (%)
  • 4.11 Wart Removers
    • 4.11.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.11.2 Market Share by Region, 2024 & 2034 (%)
  • 4.12 Mouth Care Products
    • 4.12.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.12.2 Market Share by Region, 2024 & 2034 (%)
  • 4.13 Botanicals
    • 4.13.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.13.2 Market Share by Region, 2024 & 2034 (%)
  • 4.14 Smoking Cessation Products
    • 4.14.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.14.2 Market Share by Region, 2024 & 2034 (%)

5 OTC Drugs & Dietary Supplements Analysis by Dosage Forms

  • 5.1 Key Findings
  • 5.2 Dosage Forms Segment: Market Attractiveness Index
  • 5.3 OTC Drugs & Dietary Supplements Size Estimation and Forecast by Dosage Forms
  • 5.4 Tablets
    • 5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.4.2 Market Share by Region, 2024 & 2034 (%)
  • 5.5 Capsules
    • 5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.5.2 Market Share by Region, 2024 & 2034 (%)
  • 5.6 Powder
    • 5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.6.2 Market Share by Region, 2024 & 2034 (%)
  • 5.7 Ointments
    • 5.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.7.2 Market Share by Region, 2024 & 2034 (%)
  • 5.8 Soft Capsules
    • 5.8.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.8.2 Market Share by Region, 2024 & 2034 (%)
  • 5.9 Liquids
    • 5.9.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.9.2 Market Share by Region, 2024 & 2034 (%)
  • 5.10 Others
    • 5.10.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.10.2 Market Share by Region, 2024 & 2034 (%)

6 OTC Drugs & Dietary Supplements Analysis by Distribution Channel

  • 6.1 Key Findings
  • 6.2 Distribution Channel Segment: Market Attractiveness Index
  • 6.3 OTC Drugs & Dietary Supplements Size Estimation and Forecast by Distribution Channel
  • 6.4 Pharmacies
    • 6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.4.2 Market Share by Region, 2024 & 2034 (%)
  • 6.5 Vitamin & Health Food Store
    • 6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.5.2 Market Share by Region, 2024 & 2034 (%)
  • 6.6 Online Pharmacy
    • 6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.6.2 Market Share by Region, 2024 & 2034 (%)
  • 6.7 Grocery Stores
    • 6.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.7.2 Market Share by Region, 2024 & 2034 (%)

7 OTC Drugs & Dietary Supplements Analysis by Product Type

  • 7.1 Key Findings
  • 7.2 Product Type Segment: Market Attractiveness Index
  • 7.3 OTC Drugs & Dietary Supplements Size Estimation and Forecast by Product Type
  • 7.4 Branded
    • 7.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.4.2 Market Share by Region, 2024 & 2034 (%)
  • 7.5 Generic
    • 7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.5.2 Market Share by Region, 2024 & 2034 (%)

8 OTC Drugs & Dietary Supplements Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America OTC Drugs & Dietary Supplements Analysis

  • 9.1 Key Findings
  • 9.2 North America OTC Drugs & Dietary Supplements Attractiveness Index
  • 9.3 North America OTC Drugs & Dietary Supplements by Country, 2024, 2029 & 2034 (US$ Billion)
  • 9.4 North America OTC Drugs & Dietary Supplements Size Estimation and Forecast by Country
  • 9.5 North America OTC Drugs & Dietary Supplements Size Estimation and Forecast by Categories
  • 9.6 North America OTC Drugs & Dietary Supplements Size Estimation and Forecast by Dosage Forms
  • 9.7 North America OTC Drugs & Dietary Supplements Size Estimation and Forecast by Distribution Channel
  • 9.8 North America OTC Drugs & Dietary Supplements Size Estimation and Forecast by Product Type
  • 9.9 U.S. OTC Drugs & Dietary Supplements Analysis
  • 9.10 Canada OTC Drugs & Dietary Supplements Analysis

10 Europe OTC Drugs & Dietary Supplements Analysis

  • 10.1 Key Findings
  • 10.2 Europe OTC Drugs & Dietary Supplements Attractiveness Index
  • 10.3 Europe OTC Drugs & Dietary Supplements by Country, 2024, 2029 & 2034 (US$ Billion)
  • 10.4 Europe OTC Drugs & Dietary Supplements Size Estimation and Forecast by Country
  • 10.5 Europe OTC Drugs & Dietary Supplements Size Estimation and Forecast by Categories
  • 10.6 Europe OTC Drugs & Dietary Supplements Size Estimation and Forecast by Dosage Forms
  • 10.7 Europe OTC Drugs & Dietary Supplements Size Estimation and Forecast by Distribution Channel
  • 10.8 Europe OTC Drugs & Dietary Supplements Size Estimation and Forecast by Product Type
  • 10.9 Germany OTC Drugs & Dietary Supplements Analysis
  • 10.10 France OTC Drugs & Dietary Supplements Analysis
  • 10.11 UK OTC Drugs & Dietary Supplements Analysis
  • 10.12 Italy OTC Drugs & Dietary Supplements Analysis
  • 10.13 Spain OTC Drugs & Dietary Supplements Analysis
  • 10.14 Russia OTC Drugs & Dietary Supplements Analysis
  • 10.15 Rest of Europe OTC Drugs & Dietary Supplements Analysis

11 Asia Pacific OTC Drugs & Dietary Supplements Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific OTC Drugs & Dietary Supplements Attractiveness Index
  • 11.3 Asia Pacific OTC Drugs & Dietary Supplements by Country, 2024, 2029 & 2034 (US$ Billion)
  • 11.4 Asia Pacific OTC Drugs & Dietary Supplements Size Estimation and Forecast by Country
  • 11.5 Asia Pacific OTC Drugs & Dietary Supplements Size Estimation and Forecast by Categories
  • 11.6 Asia Pacific OTC Drugs & Dietary Supplements Size Estimation and Forecast by Dosage Forms
  • 11.7 Asia Pacific OTC Drugs & Dietary Supplements Size Estimation and Forecast by Distribution Channel
  • 11.8 Asia Pacific OTC Drugs & Dietary Supplements Size Estimation and Forecast by Product Type
  • 11.9 Japan OTC Drugs & Dietary Supplements Analysis
  • 11.10 China OTC Drugs & Dietary Supplements Analysis
  • 11.11 India OTC Drugs & Dietary Supplements Analysis
  • 11.12 Australia OTC Drugs & Dietary Supplements Analysis
  • 11.13 South Korea OTC Drugs & Dietary Supplements Analysis
  • 11.14 Rest of Asia Pacific OTC Drugs & Dietary Supplements Analysis

12 Latin America OTC Drugs & Dietary Supplements Analysis

  • 12.1 Key Findings
  • 12.2 Latin America OTC Drugs & Dietary Supplements Attractiveness Index
  • 12.3 Latin America OTC Drugs & Dietary Supplements by Country, 2024, 2029 & 2034 (US$ Billion)
  • 12.4 Latin America OTC Drugs & Dietary Supplements Size Estimation and Forecast by Country
  • 12.5 Latin America OTC Drugs & Dietary Supplements Size Estimation and Forecast by Categories
  • 12.6 Latin America OTC Drugs & Dietary Supplements Size Estimation and Forecast by Dosage Forms
  • 12.7 Latin America OTC Drugs & Dietary Supplements Size Estimation and Forecast by Distribution Channel
  • 12.8 Latin America OTC Drugs & Dietary Supplements Size Estimation and Forecast by Product Type
  • 12.9 Brazil OTC Drugs & Dietary Supplements Analysis
  • 12.10 Mexico OTC Drugs & Dietary Supplements Analysis
  • 12.11 Rest of Latin America OTC Drugs & Dietary Supplements Analysis

13 MEA OTC Drugs & Dietary Supplements Analysis

  • 13.1 Key Findings
  • 13.2 MEA OTC Drugs & Dietary Supplements Attractiveness Index
  • 13.3 MEA OTC Drugs & Dietary Supplements by Country, 2024, 2029 & 2034 (US$ Billion)
  • 13.4 MEA OTC Drugs & Dietary Supplements Size Estimation and Forecast by Country
  • 13.5 MEA OTC Drugs & Dietary Supplements Size Estimation and Forecast by Categories
  • 13.6 MEA OTC Drugs & Dietary Supplements Size Estimation and Forecast by Dosage Forms
  • 13.7 MEA OTC Drugs & Dietary Supplements Size Estimation and Forecast by Distribution Channel
  • 13.8 MEA OTC Drugs & Dietary Supplements Size Estimation and Forecast by Product Type
  • 13.9 GCC OTC Drugs & Dietary Supplements Analysis
  • 13.10 South Africa OTC Drugs & Dietary Supplements Analysis
  • 13.11 Rest of MEA OTC Drugs & Dietary Supplements Analysis

14 Company Profiles

  • 14.1 Competitive Landscape, 2023
  • 14.2 Strategic Outlook
  • 14.3 Abbott
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Financial Analysis
      • 14.3.3.1 Net Revenue, 2017-2022
      • 14.3.3.2 R&D, 2017-2022
    • 14.3.4 Product Benchmarking
    • 14.3.5 Strategic Outlook
  • 14.4 Amway Corporation
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Financial Analysis
      • 14.4.3.1 Net Revenue, 2017-2022
    • 14.4.4 Product Benchmarking
    • 14.4.5 Strategic Outlook
  • 14.5 Bayer AG
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Financial Analysis
      • 14.5.3.1 Net Revenue, 2017-2022
      • 14.5.3.2 R&D, 2017-2022
      • 14.5.3.3 Regional Market Shares, 2022
    • 14.5.4 Product Benchmarking
    • 14.5.5 Strategic Outlook
  • 14.6 Cipla, Inc.
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Financial Analysis
      • 14.6.3.1 Net Revenue, 2017-2022
      • 14.6.3.2 Regional Market Shares, 2022
    • 14.6.4 Product Benchmarking
    • 14.6.5 Strategic Outlook
  • 14.7 Dr. Reddy's Laboratories Ltd.
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Financial Analysis
      • 14.7.3.1 Net Revenue, 2017-2022
      • 14.7.3.2 R&D, 2017-2022
      • 14.7.3.3 Regional Market Shares, 2022
    • 14.7.4 Product Benchmarking
    • 14.7.5 Strategic Outlook
  • 14.8 Glenmark Pharmaceuticals Ltd
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Financial Analysis
      • 14.8.3.1 Net Revenue, 2017-2022
      • 14.8.3.2 Regional Market Shares, 2022
    • 14.8.4 Product Benchmarking
    • 14.8.5 Strategic Outlook
  • 14.9 GlaxoSmithKline plc
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Financial Analysis
      • 14.9.3.1 Net Revenue, 2017-2022
      • 14.9.3.2 R&D, 2017-2022
      • 14.9.3.3 Regional Market Shares, 2022
    • 14.9.4 Product Benchmarking
    • 14.9.5 Strategic Outlook
  • 14.10 Herbalife Nutrition
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Financial Analysis
      • 14.10.3.1 Net Revenue, 2017-2022
      • 14.10.3.2 Regional Market Shares, 2022
    • 14.10.4 Product Benchmarking
    • 14.10.5 Strategic Outlook
  • 14.11 Kenvue Inc. (Previously J & J Services Business Division)
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Financial Analysis
      • 14.11.3.1 Net Revenue, 2017-2022
      • 14.11.3.2 R&D, 2017-2022
      • 14.11.3.3 Regional Market Shares, 2022
    • 14.11.4 Product Benchmarking
    • 14.11.5 Strategic Outlook
  • 14.12 Nestle SA
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Financial Analysis
      • 14.12.3.1 Net Revenue, 2017-2022
      • 14.12.3.2 R&D, 2017-2022
      • 14.12.3.3 Regional Market Shares, 2022
    • 14.12.4 Product Benchmarking
    • 14.12.5 Strategic Outlook
  • 14.13 Perrigo Company Inc,
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Financial Analysis
      • 14.13.3.1 Net Revenue, 2017-2022
      • 14.13.3.2 R&D, 2017-2022
      • 14.13.3.3 Regional Market Shares, 2022
    • 14.13.4 Product Benchmarking
    • 14.13.5 Strategic Outlook
  • 14.14 Pfizer Inc.
    • 14.14.1 Company Snapshot
    • 14.14.2 Company Overview
    • 14.14.3 Financial Analysis
      • 14.14.3.1 Net Revenue, 2017-2022
      • 14.14.3.2 R&D, 2017-2022
      • 14.14.3.3 Regional Market Shares, 2022
    • 14.14.4 Product Benchmarking
    • 14.14.5 Strategic Outlook
  • 14.15 Sanofi
    • 14.15.1 Company Snapshot
    • 14.15.2 Company Overview
    • 14.15.3 Financial Analysis
      • 14.15.3.1 Net Revenue, 2017-2022
      • 14.15.3.2 R&D, 2017-2022
    • 14.15.4 Product Benchmarking
    • 14.15.5 Strategic Outlook
  • 14.16 Sun Pharmaceutical Industries Ltd
    • 14.16.1 Company Snapshot
    • 14.16.2 Company Overview
    • 14.16.3 Financial Analysis
      • 14.16.3.1 Net Revenue, 2017-2022
      • 14.16.3.2 Regional Market Shares, 2022
    • 14.16.4 Product Benchmarking
    • 14.16.5 Strategic Outlook

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from Visiongain
  • 15.2 Recommendations for Market Players

List of Tables

  • Table 1 OTC Drugs & Dietary Supplements Snapshot, 2024 & 2034 (US$ Billion, CAGR %)
  • Table 2 OTC Drugs & Dietary Supplements Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 3 OTC Drugs & Dietary Supplements Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 4 OTC Drugs & Dietary Supplements Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 5 OTC Drugs & Dietary Supplements Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 6 OTC Drugs & Dietary Supplements Forecast by Categories, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 7 Analgesics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 8 Cold, Cough and Flu Products Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 9 Gastrointestinal Products Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 10 Ophthalmic Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 11 Feminine Care Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 12 Vitamin and Dietary Supplements Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 13 Sleep Aids Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 14 Wart Removers Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 15 Mouth Care Products Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 16 Botanicals Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 17 Smoking Cessation Products Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 18 OTC Drugs & Dietary Supplements Forecast by Dosage Forms, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 19 Tablets Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 20 Capsules Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 21 Powder Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 22 Ointments Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 23 Soft Capsules Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 24 Liquids Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 25 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 26 OTC Drugs & Dietary Supplements Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 27 Pharmacies Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 28 Vitamin & Health Food Store Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 29 Online Pharmacy Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 30 Grocery Stores Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 31 OTC Drugs & Dietary Supplements Product Type, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 32 Branded Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 33 Generic Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 34 OTC Drugs & Dietary Supplements Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 35 North America OTC Drugs & Dietary Supplements Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 36 OTC Drugs & Dietary Supplements Forecast by Categories, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 37 North America OTC Drugs & Dietary Supplements Forecast by Dosage Forms, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 38 OTC Drugs & Dietary Supplements Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 39 North America OTC Drugs & Dietary Supplements Product Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 40 U.S. OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 41 Canada OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 42 Europe OTC Drugs & Dietary Supplements Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 43 Europe OTC Drugs & Dietary Supplements Forecast by Categories, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 44 Europe OTC Drugs & Dietary Supplements Forecast by Dosage Forms, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 45 OTC Drugs & Dietary Supplements Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 46 Europe OTC Drugs & Dietary Supplements Product Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 47 Germany OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 48 France OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 49 UK OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 50 Italy OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 51 Spain OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 52 Russia OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 53 Rest of Europe OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 54 Asia Pacific OTC Drugs & Dietary Supplements Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 55 Asia Pacific OTC Drugs & Dietary Supplements Forecast by Categories, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 56 OTC Drugs & Dietary Supplements Forecast by Dosage Forms, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 57 OTC Drugs & Dietary Supplements Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 58 Asia Pacific OTC Drugs & Dietary Supplements Product Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 59 Japan OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 60 China OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 61 India OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 62 Australia OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 63 South Korea OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 64 Rest of Asia Pacific OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 65 Latin America OTC Drugs & Dietary Supplements Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 66 OTC Drugs & Dietary Supplements Forecast by Categories, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 67 OTC Drugs & Dietary Supplements Forecast by Dosage Forms, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 68 OTC Drugs & Dietary Supplements Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 69 Latin America OTC Drugs & Dietary Supplements Product Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 70 Brazil OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 71 Mexico OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 72 Rest of Latin America OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 73 MEA OTC Drugs & Dietary Supplements Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 74 OTC Drugs & Dietary Supplements Forecast by Categories, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 75 OTC Drugs & Dietary Supplements Forecast by Dosage Forms, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 76 OTC Drugs & Dietary Supplements Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 77 MEA OTC Drugs & Dietary Supplements Product Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 78 GCC OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 79 South Africa OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 80 Rest of MEA OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 81 Strategic Outlook
  • Table 82 Abbott: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 83 Abbott: Product Benchmarking
  • Table 84 Abbott: Strategic Outlook
  • Table 85 Amway Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 86 Amway Corporation: Product Benchmarking
  • Table 87 Amway Corporation: Strategic Outlook
  • Table 88 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 89 Bayer AG: Product Benchmarking
  • Table 90 Bayer AG: Strategic Outlook
  • Table 91 Cipla, Inc. Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 92 Cipla, Inc.: Product Benchmarking
  • Table 93 Cipla, Inc.: Strategic Outlook
  • Table 94 Dr. Reddy's Laboratories Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 95 Dr. Reddy's Laboratories Ltd: Product Benchmarking
  • Table 96 Dr. Reddy's Laboratories Ltd: Strategic Outlook
  • Table 97 Glenmark Pharmaceuticals Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 98 Glenmark Pharmaceuticals Ltd: Product Benchmarking
  • Table 99 Glenmark Pharmaceuticals Ltd: Strategic Outlook
  • Table 100 GlaxoSmithKline plc; Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 101 GlaxoSmithKline plc: Product Benchmarking
  • Table 102 GlaxoSmithKline plc: Strategic Outlook
  • Table 103 Herbalife Nutrition: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 104 Herbalife Nutrition: Product Benchmarking
  • Table 105 Herbalife Nutrition: Strategic Outlook
  • Table 106 Kenvue Inc. (Previously J & J Services Business Division).: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 107 Kenvue Inc. (Previously J & J Services Business Division): Product Benchmarking
  • Table 108 Kenvue Inc. (Previously J & J Services Business Division): Strategic Outlook
  • Table 109 Nestle SA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 110 Nestle SA: Product Benchmarking
  • Table 111 Nestle SA: Strategic Outlook
  • Table 112 Perrigo Company Inc, Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 113 Perrigo Company Inc, Product Benchmarking
  • Table 114 Perrigo Company Inc, Strategic Outlook
  • Table 115 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 116 Pfizer Inc.: Product Benchmarking
  • Table 117 Pfizer Inc.: Strategic Outlook
  • Table 118 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 119 Sanofi: Product Benchmarking
  • Table 120 Sanofi: Strategic Outlook
  • Table 121 Sun Pharmaceutical Industries Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 122 Sun Pharmaceutical Industries Ltd: Product Benchmarking
  • Table 123 Sun Pharmaceutical Industries Ltd: Strategic Outlook
  •  

List of Figures

  • Figure 1 OTC Drugs & Dietary Supplements Segmentation
  • Figure 2 OTC Drugs & Dietary Supplements Market by Categories: Market Attractiveness Index
  • Figure 3 OTC Drugs & Dietary Supplements by Dosage Forms: Market Attractiveness Index
  • Figure 4 OTC Drugs & Dietary Supplements by Distribution Channel: Market Attractiveness Index
  • Figure 5 OTC Drugs & Dietary Supplements by Product Type: Market Attractiveness Index
  • Figure 6 OTC Drugs & Dietary Supplements Attractiveness Index by Region
  • Figure 7 OTC Drugs & Dietary Supplements: Market Dynamics
  • Figure 8 OTC Drugs & Dietary Supplements by Region, 2024-2034 (US$ Billion, AGR %): "V" Shaped Recovery
  • Figure 9 OTC Drugs & Dietary Supplements by Region, 2024-2034 (US$ Billion, AGR %): "U" Shaped Recovery
  • Figure 10 OTC Drugs & Dietary Supplements by Region, 2024-2034 (US$ Billion, AGR %): "W" Shaped Recovery
  • Figure 11 OTC Drugs & Dietary Supplements by Region, 2024-2034 (US$ Billion, AGR %): "L" Shaped Recovery
  • Figure 12 OTC Drugs & Dietary Supplements Market: Porter's Five Forces Analysis
  • Figure 13 OTC Drugs & Dietary Supplements: PEST Analysis
  • Figure 14 OTC Drugs & Dietary Supplements by Categories: Market Attractiveness Index
  • Figure 15 OTC Drugs & Dietary Supplements Forecast by Categories, 2024-2034 (US$ Billion, AGR %)
  • Figure 16 OTC Drugs & Dietary Supplements Share Forecast by Categories, 2024, 2029, 2034 (%)
  • Figure 17 Analgesics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 18 Analgesics Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 19 Cold, Cough and Flu Products Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 20 Cold, Cough and Flu Products Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 21 Gastrointestinal Products Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 22 Gastrointestinal Products Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 23 Ophthalmic Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 24 Ophthalmic Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 25 Feminine Care Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 26 Feminine Care Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 27 Vitamin and Dietary Supplements Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 28 Vitamin and Dietary Supplements Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 29 Sleep Aids Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 30 Sleep Aids Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 31 Wart Removers Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 32 Wart Removers Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 33 Mouth Care Products Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 34 Mouth Care Products Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 35 Botanicals Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 36 Botanicals Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 37 Smoking Cessation Products Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 38 Smoking Cessation Products Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 39 OTC Drugs & Dietary Supplements by Dosage Forms: Market Attractiveness Index
  • Figure 40 OTC Drugs & Dietary Supplements Forecast by Dosage Forms, 2024-2034 (US$ Billion, AGR %)
  • Figure 41 OTC Drugs & Dietary Supplements Share Forecast by Dosage Forms, 2024, 2029, 2034 (%)
  • Figure 42 Tablets Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 43 Tablets Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 44 Capsules Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 45 Capsules Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 46 Powder Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 47 Powder Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 48 Ointments Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 49 Ointments Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 50 Soft Capsules Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 51 Soft Capsules Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 52 Liquids Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 53 Liquids Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 54 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 55 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 56 OTC Drugs & Dietary Supplements by Distribution Channel: Market Attractiveness Index
  • Figure 57 OTC Drugs & Dietary Supplements Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
  • Figure 58 Active Pharmaceutical Ingredients Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
  • Figure 59 Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 60 Pharmacies Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 61 Vitamin & Health Food Store Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 62 Vitamin & Health Food Store Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 63 Online Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 64 Online Pharmacy Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 65 Grocery Stores Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 66 Grocery Stores Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 67 OTC Drugs & Dietary Supplements by Product Type: Market Attractiveness Index
  • Figure 68 OTC Drugs & Dietary Supplements Forecast by Product Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 69 OTC Drugs & Dietary Supplements Share Forecast by Product Type, 2024, 2029, 2034 (%)
  • Figure 70 Branded Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 71 Branded Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 72 Generic Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 73 Generic Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 74 OTC Drugs & Dietary Supplements Forecast by Region 2023 and 2033 (Revenue, CAGR %)
  • Figure 75 Active Pharmaceutical Ingredients Market Share Forecast by Region 2024, 2029, 2034 (%)
  • Figure 76 OTC Drugs & Dietary Supplements by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 77 North America OTC Drugs & Dietary Supplements Attractiveness Index
  • Figure 78 North America OTC Drugs & Dietary Supplements by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 79 North America OTC Drugs & Dietary Supplements Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 80 North America OTC Drugs & Dietary Supplements Share Forecast by Country, 2024 & 2034 (%)
  • Figure 81 North America OTC Drugs & Dietary Supplements Forecast by Categories, 2024-2034 (US$ Billion, AGR %)
  • Figure 82 North America OTC Drugs & Dietary Supplements Share Forecast by Categories, 2024 & 2034 (%)
  • Figure 83 North America OTC Drugs & Dietary Supplements Forecast by Dosage Forms, 2024-2034 (US$ Billion, AGR %)
  • Figure 84 North America OTC Drugs & Dietary Supplements Share Forecast by Dosage Forms, 2024 & 2034 (%)
  • Figure 85 North America OTC Drugs & Dietary Supplements Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
  • Figure 86 North America OTC Drugs & Dietary Supplements Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 87 North America OTC Drugs & Dietary Supplements Forecast by Product Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 88 North America OTC Drugs & Dietary Supplements Share Forecast by Product Type, 2024 & 2034 (%)
  • Figure 89 U.S. OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 90 Canada OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 91 Europe OTC Drugs & Dietary Supplements Attractiveness Index
  • Figure 92 Europe OTC Drugs & Dietary Supplements by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 93 Europe OTC Drugs & Dietary Supplements Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 94 Europe OTC Drugs & Dietary Supplements Share Forecast by Country, 2024 & 2034 (%)
  • Figure 95 Europe OTC Drugs & Dietary Supplements Forecast by Categories, 2024-2034 (US$ Billion, AGR %)
  • Figure 96 Europe OTC Drugs & Dietary Supplements Share Forecast by Categories, 2024 & 2034 (%)
  • Figure 97 Europe OTC Drugs & Dietary Supplements Forecast by Dosage Forms, 2024-2034 (US$ Billion, AGR %)
  • Figure 98 Europe OTC Drugs & Dietary Supplements Share Forecast by Dosage Forms, 2024 & 2034 (%)
  • Figure 99 Europe OTC Drugs & Dietary Supplements Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
  • Figure 100 Europe OTC Drugs & Dietary Supplements Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 101 Europe OTC Drugs & Dietary Supplements Forecast by Product Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 102 Europe OTC Drugs & Dietary Supplements Share Forecast by Product Type, 2024 & 2034 (%)
  • Figure 103 Germany OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 104 France OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 105 UK OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 106 Italy OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 107 Spain OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 108 Russia OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 109 Rest of Europe OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 110 Asia Pacific OTC Drugs & Dietary Supplements Attractiveness Index
  • Figure 111 Asia Pacific OTC Drugs & Dietary Supplements by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 112 Asia Pacific OTC Drugs & Dietary Supplements Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 113 Asia Pacific OTC Drugs & Dietary Supplements Share Forecast by Country, 2024 & 2034 (%)
  • Figure 114 Asia Pacific OTC Drugs & Dietary Supplements Forecast by Categories, 2024-2034 (US$ Billion, AGR %)
  • Figure 115 Asia Pacific OTC Drugs & Dietary Supplements Share Forecast by Categories, 2024 & 2034 (%)
  • Figure 116 Asia Pacific OTC Drugs & Dietary Supplements Forecast by Dosage Forms, 2024-2034 (US$ Billion, AGR %)
  • Figure 117 Asia Pacific OTC Drugs & Dietary Supplements Share Forecast by Dosage Forms, 2024 & 2034 (%)
  • Figure 118 Asia Pacific OTC Drugs & Dietary Supplements Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
  • Figure 119 Asia Pacific OTC Drugs & Dietary Supplements Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 120 Asia Pacific OTC Drugs & Dietary Supplements Forecast by Product Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 121 Asia Pacific OTC Drugs & Dietary Supplements Share Forecast by Product Type, 2024 & 2034 (%)
  • Figure 122 Japan OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 123 China OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 124 India OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 125 Australia OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 126 South Korea OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 127 Rest of Asia Pacific OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 128 Latin America OTC Drugs & Dietary Supplements Attractiveness Index
  • Figure 129 Latin America OTC Drugs & Dietary Supplements by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 130 Latin America OTC Drugs & Dietary Supplements Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 131 Latin America OTC Drugs & Dietary Supplements Share Forecast by Country, 2024 & 2034 (%)
  • Figure 132 Latin America OTC Drugs & Dietary Supplements Forecast by Categories, 2024-2034 (US$ Billion, AGR %)
  • Figure 133 Latin America OTC Drugs & Dietary Supplements Share Forecast by Categories, 2024 & 2034 (%)
  • Figure 134 Latin America OTC Drugs & Dietary Supplements Forecast by Dosage Forms, 2024-2034 (US$ Billion, AGR %)
  • Figure 135 Latin America OTC Drugs & Dietary Supplements Share Forecast by Dosage Forms, 2024 & 2034 (%)
  • Figure 136 Latin America OTC Drugs & Dietary Supplements Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
  • Figure 137 Latin America OTC Drugs & Dietary Supplements Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 138 Latin America OTC Drugs & Dietary Supplements Forecast by Product Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 139 Latin America OTC Drugs & Dietary Supplements Share Forecast by Product Type, 2024 & 2034 (%)
  • Figure 140 Brazil OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 141 Mexico OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 142 Rest of Latin America OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 143 MEA OTC Drugs & Dietary Supplements Attractiveness Index
  • Figure 144 MEA OTC Drugs & Dietary Supplements by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 145 MEA OTC Drugs & Dietary Supplements Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 146 MEA OTC Drugs & Dietary Supplements Share Forecast by Country, 2024 & 2034 (%)
  • Figure 147 MEA OTC Drugs & Dietary Supplements Forecast by Categories, 2024-2034 (US$ Billion, AGR %)
  • Figure 148 MEA OTC Drugs & Dietary Supplements Share Forecast by Categories, 2024 & 2034 (%)
  • Figure 149 MEA OTC Drugs & Dietary Supplements Forecast by Dosage Forms, 2024-2034 (US$ Billion, AGR %)
  • Figure 150 MEA OTC Drugs & Dietary Supplements Share Forecast by Dosage Forms, 2024 & 2034 (%)
  • Figure 151 MEA OTC Drugs & Dietary Supplements Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
  • Figure 152 MEA OTC Drugs & Dietary Supplements Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 153 MEA OTC Drugs & Dietary Supplements Forecast by Product Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 154 MEA OTC Drugs & Dietary Supplements Share Forecast by Product Type, 2024 & 2034 (%)
  • Figure 155 GCC OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 156 South Africa OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 157 Rest of MEA OTC Drugs & Dietary Supplements Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 158 OTC Drugs & Dietary Supplements Market: Company Share, 2023
  • Figure 159 Abbott: Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 160 Abbott: R&D, 2017-2022 (US$ Million, AGR %)
  • Figure 161 Amway Corporation: Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 162 Bayer AG: Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 163 Bayer AG: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 164 Bayer AG: Regional Market Shares, 2022
  • Figure 165 Cipla, Inc. Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 166 Cipla Inc,. Regional Market Shares, 2022
  • Figure 167 Dr. Reddy's Laboratories Ltd: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 168 Dr. Reddy's Laboratories Ltd: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 169 Dr. Reddy's Laboratories Ltd: Regional Market Shares, 2022
  • Figure 170 Glenmark Pharmaceuticals Ltd: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 171 Glenmark Pharmaceuticals Ltd: Regional Market Shares, 2022
  • Figure 172 GlaxoSmithKline plc ; Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 173 GlaxoSmithKline plc; R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 174 GlaxoSmithKline plc ; Regional Market Shares, 2022
  • Figure 175 Herbalife Nutrition: Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 176 Herbalife Nutrition: Regional Market Shares, 2022
  • Figure 177 Kenvue Inc. (Previously J & J Services Business Division).: Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 178 Kenvue Inc. (Previously J & J Services Business Division).: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 179 Kenvue Inc. (Previously J & J Services Business Division): Regional Market Shares, 2022
  • Figure 180 Nestle SA: Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 181 Nestle SA: R&D, 2017-2022 (US$ Million, AGR %)
  • Figure 182 Nestle SA: Regional Market Shares, 2022
  • Figure 183 Perrigo Company Inc, Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 184 Perrigo Company Inc, R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 185 Perrigo Company Inc, Regional Market Shares, 2022
  • Figure 186 Pfizer Inc.: Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 187 Pfizer Inc.: R&D, 2017-2022 (US$ Million, AGR %)
  • Figure 188 Pfizer Inc.: Regional Market Shares, 2022
  • Figure 189 Sanofi: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 190 Sanofi: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 191 Sun Pharmaceutical Industries Ltd: Net Revenue, 2017-2022 (US$ Million, AGR %)
  • Figure 192 Sun Pharmaceutical Industries Ltd: Regional Market Shares, 2022